Cervical cancer targeted therapy! Seattle Genetic Antibody Drug Coupling Tisotumab Vedotin Key PHASE II Study Positive Results!

, 2020 /
PRNewswire/ --SeattleGenetic
seditography (Seattle Genetics) has announced positive top-line results from the Antibody Drug Couple (ADC) tisotumab vedotin for cervical cancer phase II innovaTV 204this is an ongoing one-arm, global, multicenter study of 101 patients with recurrent or metastatic cervical cancer who have previously undergone double chemotherapy (combination or non-combination of bevam) but progression, or have received at least two treatments to treat metastatic diseasesThe study assessed the efficacy and safety of tisotumab vedotin (administered every 3 weeks)The primary endpoints are the objective mitigation rate (ORR) assessed by the Blind Independent Center Review (BICR), and key secondary endpoints include mitigation duration (DOR), progression-free survival (PFS), total lifetime (OS), safety, and toleranceresults show that the BICR review determined that theThe ORR was 24% and the median DOR was 8.3 monthsIn the study, the most common therapeutic-related adverse events (-20%) included hair loss, nosebleeds, nausea, conjunctivitis, fatigue, and dry eye diseaseDetails of the study will be published at the upcoming medicaltisotumab vedotin is an antibody drug conjugate (ADC) that targets tissue factor (tissue factor, TF), which is expressed on cervical cancer cells and promotes the growth, angiogenesis and metastasis oftumorsPreviously treated for recurrent and/or metastatic cervical cancer, standardtherapy usually showed a very limited objective remission rate, usually below 15%, while the median total lifetime (OS) was only 6.0-9.4 months "Recurrent or metastatic cervical cancer with progressive progression after first-line chemotherapy has limited treatment options available and there is significant unmet demand for new treatment options," said Roger Dansey, M.D., chief medical officer at the Genetic
sediton in Seattle, Tisotumab vedotin has proven to be clinically significant and long-lasting objective response, safe lying, and we look forward to discussing with the FDA the possibility of submitting a Biologics License Application (BLA) to support accelerated approval "
cervical cancer originates in cervical cells and remains one of the leading causes of cancer death in women worldwide, killing more than 311,000 women each year, the vast majority of them in developing countries In developed countries, routine medical examinations and hpv vaccination have reduced the incidence of cervical cancer Despite these advances, many women are still diagnosed cervical cancer, which often recurs or metastasis and can have devastating effects cervical cancer originated in cervical cells and is one of the leading causes of cancer death in women worldwide It is estimated that in 2018, about 13,000 women in the United States will be diagnosed with cervical cancer and about 4,000 will die Globally, more than 311,000 women die each year from cervical cancer, the vast majority of them in developing countries In developed countries, routine medical examinations and human papillomavirus (HPV) vaccines have reduced the incidence of cervical cancer Despite these advances, many women are still diagnosed cervical cancer, which can have devastating effects, especially in recurrent and/or metastatic diseases tsotumab vedotin is a research ADC drug that combines Genmab's TF-targeted monoantitic tisotumab with ADC technology from Seattle-
Genetics , which targets TF antigens on cancer cells and delivers the cell venom MMAE (monomethyl monoustatin E, monomethyl auristatin E) directly to cancer cells In cancer biology, TF is a protein involved in tumor signaling and angiogenesis, overexpressing in the vast majority of cervical cancer patients and many other solid tumors, including ovarian, lung, pancreatic, colorectal, and head and neck cancers Based on the high expression and rapid internalization of TF factors in many solid tumors, TF has become an ideal target for the development of ADC drugs currently, tisotumab vedotin is being developed by Seattle Genetics Corporation and Genmab as a monodrug therapy or a combination of other therapies to treat recurrent and/or metastatic cervical and/or metastatic cervical, ovarian and other tumor In addition, the two parties are evaluating the weekly or every 3 weeks of the drug administration programme (BioValleyBioon.com) original source: Seattle Genetics Announces Positive Topline Results from Phase 2 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cancer